[go: up one dir, main page]

PE20091258A1 - PYRIDINE DERIVATIVES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS - Google Patents

PYRIDINE DERIVATIVES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS

Info

Publication number
PE20091258A1
PE20091258A1 PE2008002003A PE2008002003A PE20091258A1 PE 20091258 A1 PE20091258 A1 PE 20091258A1 PE 2008002003 A PE2008002003 A PE 2008002003A PE 2008002003 A PE2008002003 A PE 2008002003A PE 20091258 A1 PE20091258 A1 PE 20091258A1
Authority
PE
Peru
Prior art keywords
halo
pyridine derivatives
pyridin
phenyl
methyl
Prior art date
Application number
PE2008002003A
Other languages
Spanish (es)
Inventor
Anne Marie Jeanne Bouillot
Nerina Dodic
Francoise Jeanne Gellibert
Olivier Mirguet
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0723629A external-priority patent/GB0723629D0/en
Priority claimed from GB0813714A external-priority patent/GB0813714D0/en
Priority claimed from GB0816960A external-priority patent/GB0816960D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20091258A1 publication Critical patent/PE20091258A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRIDINA DE FORMULA (I), DONDE R1 Y R2 SON H, HALO, CF3, ALQUILO C1-C4, ALILO; Y ES FENILO, PIPERIDINA, ENTRE OTROS; R4 ES H O METILO; Z ES (CH2)2, OCH2 O ESTA AUSENTE; A, J Y L SON CH O N; R5 ES H, CH3, ALCOXI C1-C4, ENTRE OTROS; R6 ES H O CH3; X ES (a); R8 ES H O HALO; R9 ES H, HALO, OCF3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 1-[6-(2-(4-(4-CIANOFENOXI)FENILMETILOXI)-FENIL)PIRIDIN-2-IL]-5-TRIFLUOROMETIL-PIRAZOL-4-CARBOXILICO, ACIDO 1-[6-(2-(2-METIL-4-(4-TRIFLUOROMETOXIFENIL)FENILMETILOXI)-FENIL)PIRIDIN-2-IL]-5-TRIFLUOROMETIL-PIRAZOL-4-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ACTIVADORES DE LA GUANILATO CICLASA SOLUBLE (sGC) Y SON UTILES EN EL TRATAMIENTO DE AFECCIONES CARDIOVASCULARES TALES COMO HIPERTENSION ARTERIAL, ATEROESCLEROSIS, ANGINA DE PECHO, ENTRE OTROSREFERRED TO A COMPOUND DERIVED FROM PYRIDINE OF FORMULA (I), WHERE R1 AND R2 ARE H, HALO, CF3, C1-C4 ALKYL, ALLYL; AND IT IS PHENYL, PIPERIDINE, AMONG OTHERS; R4 IS H O METHYL; Z IS (CH2) 2, OCH2 OR IS ABSENT; A, J, and L ARE CH O N; R5 IS H, CH3, C1-C4 ALCOXY, AMONG OTHERS; R6 IS H O CH3; X IS (a); R8 IS H OR HALO; R9 IS H, HALO, OCF3, AMONG OTHERS. PREFERRED COMPOUNDS ARE: 1- [6- (2- (4- (4-CYANOPHENOXY) PHENYLMETILOXY) -PHENYL) PYRIDIN-2-IL] -5-TRIFLUOROMETHYL-PYRAZOLE-4-CARBOXYL ACID, 1- [6- ( 2- (2-METHYL-4- (4-TRIFLUOROMETOXIFENIL) PHENYLMETILOXI) -PHENIL) PYRIDIN-2-IL] -5-TRIFLUOROMETIL-PIRAZOL-4-CARBOXILICO, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE ACTIVATORS OF SOLUBLE GUANILATE CYCLASE (sGC) AND ARE USEFUL IN THE TREATMENT OF CARDIOVASCULAR AFFECTIONS SUCH AS ARTERIAL HYPERTENSION, ATHEROSCLEROSIS, ANGINA PEAK, AMONG OTHERS

PE2008002003A 2007-12-03 2008-12-01 PYRIDINE DERIVATIVES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS PE20091258A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0723629A GB0723629D0 (en) 2007-12-03 2007-12-03 Compounds
GB0813714A GB0813714D0 (en) 2008-07-25 2008-07-25 Compounds
GB0816960A GB0816960D0 (en) 2008-09-16 2008-09-16 Compounds

Publications (1)

Publication Number Publication Date
PE20091258A1 true PE20091258A1 (en) 2009-09-12

Family

ID=40717321

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002003A PE20091258A1 (en) 2007-12-03 2008-12-01 PYRIDINE DERIVATIVES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS

Country Status (5)

Country Link
AR (1) AR069517A1 (en)
PE (1) PE20091258A1 (en)
TW (1) TW200938529A (en)
UY (1) UY31507A1 (en)
WO (1) WO2009071504A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5298129B2 (en) 2007-09-06 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション Soluble guanylate cyclase activator
WO2009081970A1 (en) * 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Process for production of heterocycle-substituted pyridine derivative
EP2264017A4 (en) 2008-04-04 2011-07-27 Takeda Pharmaceutical HETEROCYCLIC DERIVATIVE AND USE THEREOF
WO2010015652A2 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
MA33984B1 (en) 2010-02-05 2013-02-01 Bayer Ip Gmbh SGC STIMULATORS OR SGC ACTIVATORS ONLY OR IN COMBINATION WITH PDE5 INHIBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2011095553A1 (en) 2010-02-05 2011-08-11 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
US20130096160A1 (en) * 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
ES2549979T3 (en) 2010-05-26 2015-11-03 Adverio Pharma Gmbh The use of sGC stimulators, sGC activators, alone and in combinations with PDE5 inhibitors for the treatment of systemic sclerosis (EcS)
WO2011161099A1 (en) 2010-06-25 2011-12-29 Bayer Pharma Aktiengesellschaft Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
WO2012122340A1 (en) * 2011-03-10 2012-09-13 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
WO2013025425A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
CN104245663B (en) 2012-04-16 2016-10-26 东亚荣养株式会社 bicyclic compound
US8906904B2 (en) * 2012-09-07 2014-12-09 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2014095249A1 (en) 2012-12-19 2014-06-26 Basf Se Fungicidal imidazolyl and triazolyl compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
US10265314B2 (en) 2013-07-25 2019-04-23 Bayer Pharma Aktiengesellschaft SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis
CA2923393A1 (en) 2013-09-05 2015-03-12 Glaxosmithkline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use
WO2015056663A1 (en) 2013-10-15 2015-04-23 トーアエイヨー株式会社 4-aminomethylbenzoic acid derivative
WO2015095515A1 (en) 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
TW201625586A (en) 2014-07-02 2016-07-16 諾華公司 Cyclohexen-1-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
TW201625584A (en) 2014-07-02 2016-07-16 諾華公司 Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
TW201625601A (en) * 2014-07-02 2016-07-16 諾華公司 Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators
SG11201700507XA (en) 2014-07-22 2017-02-27 Boehringer Ingelheim Int Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
CN105980373A (en) * 2014-09-05 2016-09-28 葛兰素史密斯克莱知识产权发展有限公司 Novel soluble guanylate cyclase activators and their use
CR20170102A (en) 2014-09-19 2017-07-17 Glaxosmithkline Ip Dev Ltd NEW ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE AND ITS USE
JP6748113B2 (en) 2015-05-06 2020-08-26 バイエル・ファルマ・アクティエンゲゼルシャフト Use of sGC stimulants, sGC activators alone or in combination with PDE5 inhibitors for treating digital ulcers (DU) associated with systemic sclerosis (SSc)
CA2989740C (en) 2015-07-23 2023-07-11 Bayer Pharma Aktiengesellschaft Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof
EP3390386A1 (en) 2015-12-18 2018-10-24 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
CN109890379A (en) 2016-10-11 2019-06-14 拜耳制药股份公司 Combination product comprising sGC activator and mineralocorticoid receptor antagonist
WO2018153899A1 (en) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Use of activators and stimulators of sgc comprising a beta2 subunit
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
CN112055584A (en) 2018-04-30 2020-12-08 拜耳公司 Use of sGC activators and sGC stimulators for the treatment of cognitive impairment
TW202015676A (en) 2018-05-15 2020-05-01 德商拜耳廠股份有限公司 Use of 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CN111423353B (en) * 2020-04-29 2022-03-22 湖北省生物农药工程研究中心 Polysubstituted N-arylpyrrole compound and preparation method thereof
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
CA3258617A1 (en) 2022-06-09 2023-12-14 Bayer Ag Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase

Also Published As

Publication number Publication date
AR069517A1 (en) 2010-01-27
UY31507A1 (en) 2009-07-17
TW200938529A (en) 2009-09-16
WO2009071504A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
PE20091258A1 (en) PYRIDINE DERIVATIVES AS SOLUBLE GUANILATE CYCLASE ACTIVATORS
PE20091491A1 (en) NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
PE20091002A1 (en) DIPEPTIDED ANALOGS AS INHIBITORS OF THE COAGULATION FACTOR
PE20091033A1 (en) NICOTINAMIDE DERIVATIVES AS ANTI-CANCER AGENTS AND THEIR PREPARATION
EA200901379A1 (en) DERIVATIVES OF NICOTINIC ACID AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS 5 SUBTILES
PE20120355A1 (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF THE ENZYME 11ßHSD1
PE20142099A1 (en) SULFONAMIDE DERIVATIVES
PE20081545A1 (en) SULFONAMIDE DERIVATIVES AS SYNTHASE FATTY ACID INHIBITORS
PE20080453A1 (en) DERIVATIVES OF PHENYL.OXY-PHENYL-PYRIMIDINONE IN THE TREATMENT OF MALARIA
PE20081120A1 (en) HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALOPROTEINASES (MMP)
PE20120690A1 (en) DERIVATIVES OF 5-FLUOROPYRIMIDINONE
PE20051170A1 (en) PIRROL DERIVATIVES AS INHIBITORS OF FACTOR Xa
PE20060589A1 (en) PHENYLAMINOTIZOLES SUBSTITUTED AS ADENOSINE A1 AND A2b AGONISTS
PE20121474A1 (en) NEW SPIROPIPERIDINE COMPOUNDS
PE20110566A1 (en) CYCLIC INHIBITORS OF 11BETA-HYDROXIESTEROID DEHYDROGENASE 1
PE20081636A1 (en) ANTHRANILAMIDE INHIBITORS FOR AURORA KINASE
PE20110329A1 (en) PIPERIDINYL PROTEIN G-LINKED RECEPTOR AGONISTS
PE20091429A1 (en) 4- (4-CYANE-2-THIOARIL) DIHYDROPYRIMIDINONES AS INHIBITORS OF HUMAN NEUTROPHYL ELASTASE (HNE)
PE20120911A1 (en) PROLIN DERIVATIVES AS CATEPSIN INHIBITORS
CO6140060A2 (en) DERIVATIVES OF AMINOCICLOALQUIL 1,2,4-TRIAZOL AS MODULATORS OF MGLUR5
PE20081393A1 (en) QUINOLINE DERIVATIVES AS INHIBITORS OF CSF-1R
PE20081845A1 (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
PE20090813A1 (en) 11B-HYDROXIESTEROID-DEHYDROGENASE INHIBITORS
PE20040898A1 (en) NEW COMPOUNDS DERIVED FROM PYRIMIDINE
PE20040864A1 (en) HETEROBIARYL DERIVATIVES AS MATRIX METALOPROTEINASE INHIBITORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal